chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Chronic Myeloid Leukemia References

  1. Assouline S, Lipton JH. Monitoring response and resistance to treatment in chronic myeloid leukemia. Current Oncol. 2011 Apr;18(2):e71-e83. PMID: 21505592
  2. American Cancer Society. What is chronic myeloid leukemia?. American Cancer Society. http://www.cancer.org/. Feb 2016. Accessed 02 May 2016.
  3. Assouline S, Lipton JH. Monitoring response and resistance to treatment in chronic myeloid leukemia. Current Oncol. 2011 Apr;18(2):e71-e83. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070714/pdf/conc-18-e71.pdf. PMID: 21505592
  4. Baccarani M, Castagnetti F, Gugliotta G. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Disease. 2014 Jan;6(1):e2014005. doi: 10.4084/MJHID.2014.005.
  5. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet Recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug;122(6):872-884. doi: 10.1182/blood-2013-05-501569. PMID: 23803709
  6. Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2012 Oct;23(Suppl 7):vii72-vii77. doi:10.1093/annonc/mds228. PMID: 22997458
  7. Cancer Research UK. Types of treatment for chronic myeloid leukemia. Cancer Research UK. http://www.cancerresearchuk.org/. Nov 2014. Accessed 02 May 2016.
  8. Cross NC, White HE, Colomer D. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. PMID: 25652737
  9. Deeg HJ, Sandmaier BM. Determining eligibility for hematopoietic cell transplantation. UpToDate. http://www.uptodate.com/. Mar 2016. Accessed 02 May 2016.
  10. Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes. 2013 Oct;11:167. doi: 10.1186/1477-7525-11-167. PMID: 24099272
  11. National Cancer Institute. General information about chronic myelogenous leukemia (CML). National Cancer Institute. http://www.cancer.gov/. Mar 2016. Accessed 02 May 2016.
  12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia version 1.2016. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Sep 09, 2015.
  13. Negrin RS. Hematopoietic cell transplantation in chronic myeloid leukemia. UpToDate. http://www.uptodate.com/. Apr 2016. Accessed 02 May 2016.
  14. Negrin RS, Schiffer CA. Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia. UpToDate. http://www.uptodate.com/. Feb 2016. Accessed 02 May 2016.
  15. Negrin RS, Schiffer CA. Overview of the treatment of chronic myeloid leukemia. UpToDate. http://www.uptodate.com/. Feb 2016. Accessed 02 May 2016.
  16. Negrin RS, Schiffer CA. Treatment of chronic myeloid leukemia in accelerated phase. UpToDate. http://www.uptodate.com/. Jul 2015. Accessed 02 May 2016.
  17. Negrin RS, Schiffer CA. Treatment of myeloid leukemia in blast crisis. UpToDate. http://www.uptodatecom/. Sep 2014. Accessed 02 May 2016.
  18. Negrin RS, Schiffer CA. Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy. UpToDate. http://www.uptodate.com/. Apr 2016. Accessed 02 May 2016.
  19. Oehler VG. Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice. Hematology Am Soc Hematol Educ Program. 2013;2013:176-183. doi: 10.1182/asheducation-2013.1.176. PMID: 24319179
  20. Rytting ME. Chronic myelogenous leukemia. MSD Manual. http://www.msdmanuals.com/. Oct 2014. Accessed 02 May 2016.
  21. Rochau U, Kluibenschaedl M, Stenehjem D, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leuk Res Treatment. 2015;2015:982395. doi: 10.1155/2015/982395. PMID: 26783469
  22. Van Etten RA. Cellular and molecular biology of chronic myeloid leukemia. UpToDate. http://www.uptodate.com/. Apr 2016. Accessed 02 May 2016.
  23. Van Etten RA. Clinical manifestations and diagnosis of chronic myeloid leukemia. UpToDate. http://www.uptodate.com/. Apr 2016. Accessed 02 May 2016.
  24. Van Etten RA. Molecular genetics of chronic myeloid leukemia. UpToDate. http://www.uptodate.com/. Sep 2015. Accessed 02 May 2016.
  25. Waclaw J, Sacha T, Soklosa T. Imatinib in the treatment of chronic myeloid leukemia: Current perspectives on optimal dose. Cancer Therapy Advisor. http://www.cancertherapyadvisor.com/. Sep 2015. Accessed 02 May 2016.
  26. World Health Organization (WHO). Chronic myelogenous leukemia. WHO. http://www.who.int/. 2014. Accessed 02 May 2016.
  27. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology (NCCN Guidelines): chronic myeloid leukemia. Version 1.2017. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. 15 Nov 2016.
  28. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Accessed 24 Mar 2020. PMID: 32127639
  29. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Chronic myeloid leukemia. Version 3.2020. NCCN. https://www.nccn.org/. Jan 2020.
  30. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul;118(3):686-692. doi: 10.1182/blood-2010-12-319038. PMID: 21536864
  31. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998 Jun;90(11):850-858. doi: 10.1093/jnci/90.11.850. PMID: 9625174
  32. Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Jul. doi: 10.1111/bjh.16971. PMID: 32734668
  33. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Chronic myeloid leukemia. Version 2.2021. NCCN. https://www.nccn.org/. 28 Aug 2020.
  34. Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016 Jan;30(1):48-56. doi: 10.1038/leu.2015.261. PMID: 26416462
  35. Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemi. Leukemia. 2020 Aug;34(8):2138-2149. doi: 10.1038/s41375-020-0931-9. PMID: 32601376
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jan 2021
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Dr Margaret Shi, 15 Jan 2021

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).